-
Product Insights
NewNet Present Value Model: aTyr Pharma Inc’s Stalaris
Empower your strategies with our Net Present Value Model: aTyr Pharma Inc's Stalaris report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – aTyr Pharma Inc
ATyr Pharma Inc (ATyr Pharma) is a clinical-stage biotechnology company. It is engaged in the discovery and clinical development of medicines for the treatment of cancer and lung diseases. Its ATYR1923 is a clinical-stage product candidate, based on the resokine pathway, which binds to the neuropilin-2 receptor harnesses immune engagement in interstitial lung diseases and other immune-mediated diseases. It also concentrates on research and development of extracellular functionality of tRNA synthetases. ATyr Pharma also develops drugs for cancer, inflammation, neurodegenerative...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efzofitimod in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Systemic Sclerosis (Scleroderma) Drug Details: efzofitimod (ATYR-1923) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal...
-
Product Insights
NewSystemic Sclerosis (Scleroderma) – Drugs In Development, 2024
Empower your strategies with our Systemic Sclerosis (Scleroderma) – Drugs In Development, 2024 report and make more profitable business decisions. Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pain, joint pain and swelling, ulcers occurring on the fingertips, bloating, and diarrhea or constipation. Treatment includes antibiotics, pain relievers, and immunosuppressants. The Systemic Sclerosis (Scleroderma) drugs in development market research report provide comprehensive information on the therapeutics under...
-
Product Insights
NewInterstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial lung disease (ILD) is a term that covers a variety of disorders that cause scarring or inflammation of the lung tissue. The scarring or inflammation affects the ability of the lungs to transfer oxygen to the blood. ILD can be caused by many factors, such as exposure to environmental toxins, certain medications, autoimmune diseases, infections, or...
-
Product Insights
NewAcute Lung Injury – Drugs In Development, 2024
Empower your strategies with our Acute Lung Injury – Drugs In Development, 2024 report and make more profitable business decisions. Acute lung injury (ALI) is a severe and potentially life-threatening condition characterized by sudden and significant damage to the lungs, resulting in impaired gas exchange and respiratory function. ALI is now often grouped under the broader term acute respiratory distress syndrome (ARDS). ALI can result from various direct causes, including pneumonia, aspiration of gastric contents, near-drowning, inhalation of toxins or smoke,...
-
Product Insights
NewPulmonary Sarcoidosis – Drugs In Development, 2024
Empower your strategies with our Pulmonary Sarcoidosis – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary Sarcoidosis is a rare inflammatory disease that affects the multi-organs predominantly lungs and intrathoracic lymph nodes. It is characterized by the presence of granulomas in which group of cells form clusters of inflamed tissue. Younger and middle-aged groups are commonly affected and there is no specific origin causing this condition. It is differentiated into five different stages from stage 0 to...
-
Product Insights
NewSarcoidosis – Drugs In Development, 2024
Empower your strategies with our Sarcoidosis – Drugs In Development, 2024 report and make more profitable business decisions. Sarcoidosis is a systemic inflammatory disease that can affect any organ. It is characterized by the development and growth of tiny lumps of cells called granulomas. The disease usually begins in the lungs, skin, or lymph nodes. The cause of sarcoidosis is unknown. Signs and symptoms of sarcoidosis vary based on the location of the granulomas and the severity of the condition. The...
-
Product Insights
NewThrombocytopenia – Drugs In Development, 2024
Empower your strategies with our Thrombocytopenia – Drugs In Development, 2024 report and make more profitable business decisions. Thrombocytopenia refers to a lower than normal platelet count in the blood. Platelets are crucial for blood clotting and preventing bleeding. Various factors can cause thrombocytopenia, including certain medications, infections, autoimmune disorders, or conditions affecting bone marrow function. Symptoms may range from mild bruising and petechiae (small red or purple spots on the skin) to more severe bleeding in the nose, gums, or...